OncoSignature High Throughput Screening Service

Reveal the efficacy of your compounds or biologics as single agents or in combination 
across 300 cancer cell lines, in just 3 months.

The OncoSignature drug discovery screening service profiles your compounds or biologics of interest as single or combination therapies:

  • Study drug response by identifying sensitive and resistant cells
  • Aid patient stratification for your drug candidate or drug combination
  • Speed drug development by identifying drug combinations
  • Identify combination interactions with our proprietary Chalice™ software

Our OncoSignature Service includes:

  • Screen across a diverse, clinically relevant 300 cell line panel or a more focused, tissue-specific panel such as lung, lymphoma, head & neck, or breast
  • Access to a library of over 350 standard of care compounds
  • Cell lines grown in vendor-recommended media
  • 10 point, 3-fold dilution for single compounds
  • 9x9 full dose response matrix for compounds in combination
  • 72, 96, 120, or 144 h treatment times
  • Growth Inhibition measured by ATP levels

Watch the video about our drug combination screen capabilities

To learn more about our OncoSignature HTS Screening Service, take a look at our poster:

View the OncoSignature Poster

You will receive:

Single AgentsCombinations 
 Dose response curve  Dose matrix
 Doubling time Model scores including Synergy Score, Loewe Volume Score, Bliss Volume Score, and ~5 additional combination models, generated with our proprietary Chalice™ software
 IC50 and GI50
 Maximum response and more

Request More Information

Back to top